Methods for analysis of PDEF and survivin as interconnected cancer biomarkers and targets for personalized medicine
US8043815B2 · kind B2 · utility
1Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2008 |
| Grant date | Oct 25, 2011 |
| Priority date | — |
| Expiry date | Oct 26, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.